Cholinergic dysfunction in isolated rapid eye movement sleep behaviour disorder links to impending phenoconversion.
REM sleep behavior disorder
cholinergic neurons/abnormalities
dopaminergic imaging
positron emission tomography
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
revised:
10
09
2024
received:
07
06
2024
accepted:
16
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Most patients with isolated rapid eye movement sleep behaviour disorder (iRBD) progress to a parkinsonian alpha-synucleinopathy. However, time to phenoconversion shows great variation. The aim of this study was to investigate whether cholinergic and dopaminergic dysfunction in iRBD patients was associated with impending phenoconversion. Twenty-one polysomnography-confirmed iRBD patients underwent baseline Follow-up was accomplished in 17 patients. Eight patients progressed to either Parkinson's disease (n = 4) or dementia with Lewy bodies (n = 4), while nine remained non-phenoconverters. Compared with non-phenoconverters, 8-year phenoconverters had lower mean These findings suggest that cortical cholinergic dysfunction, particularly within the parietal cortex, could be a biomarker candidate for predicting short-term phenoconversion in iRBD patients. This study aligns with previous reports suggesting dopaminergic dysfunction is associated with forthcoming phenoconversion.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Most patients with isolated rapid eye movement sleep behaviour disorder (iRBD) progress to a parkinsonian alpha-synucleinopathy. However, time to phenoconversion shows great variation. The aim of this study was to investigate whether cholinergic and dopaminergic dysfunction in iRBD patients was associated with impending phenoconversion.
METHODS
METHODS
Twenty-one polysomnography-confirmed iRBD patients underwent baseline
RESULTS
RESULTS
Follow-up was accomplished in 17 patients. Eight patients progressed to either Parkinson's disease (n = 4) or dementia with Lewy bodies (n = 4), while nine remained non-phenoconverters. Compared with non-phenoconverters, 8-year phenoconverters had lower mean
CONCLUSIONS
CONCLUSIONS
These findings suggest that cortical cholinergic dysfunction, particularly within the parietal cortex, could be a biomarker candidate for predicting short-term phenoconversion in iRBD patients. This study aligns with previous reports suggesting dopaminergic dysfunction is associated with forthcoming phenoconversion.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16503Subventions
Organisme : Danish Parkinson's Association (Parkinsonforeningen)
ID : R4-A104-B60
Organisme : Instituto de Salud Carlos III
ID : CB06/05/0018
Organisme : Augustinus Fonden
ID : 23-0916
Organisme : Danmarks Frie Forskningsfond
ID : 4004-00480B
Organisme : Danmarks Frie Forskningsfond
ID : 8020-00260B
Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. 2016;15(4):405‐419. doi:10.1016/S1474-4422(16)00057-0
Bedard MA, Aghourian M, Legault‐Denis C, et al. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with (18)F‐FEOBV. Sleep Med. 2019;58:35‐41. doi:10.1016/j.sleep.2018.12.020
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181‐184. doi:10.1136/jnnp.55.3.181
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88‐100. doi:10.1212/WNL.0000000000004058
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670‐676. doi:10.1212/01.wnl.0000324625.00404.15
Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration—an update. Nat Rev Neurol. 2018;14(1):40‐55. doi:10.1038/nrneurol.2017.157
Iranzo A, Fernandez‐Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741. doi:10.1371/journal.pone.0089741
Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid‐eye‐movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010;9(11):1070‐1077. doi:10.1016/S1474-4422(10)70216-7
Chahine LM, Brumm MC, Caspell‐Garcia C, et al. Dopamine transporter imaging predicts clinically‐defined alpha‐synucleinopathy in REM sleep behavior disorder. Ann Clin Transl Neurol. 2021;8(1):201‐212. doi:10.1002/acn3.51269
Iranzo A, Santamaria J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2017;82(3):419‐428. doi:10.1002/ana.25026
Stokholm MG, Iranzo A, Ostergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid‐eye‐movement sleep behaviour disorder: a case‐control study. Lancet Neurol. 2017;16(10):789‐796. doi:10.1016/S1474-4422(17)30173-4
Pasquini J, Brooks DJ, Pavese N. The cholinergic brain in Parkinson's disease. Mov Disord Clin Pract. 2021;8(7):1012‐1026. doi:10.1002/mdc3.13319
Gersel Stokholm M, Iranzo A, Ostergaard K, et al. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. Eur J Neurol. 2020;27(4):644‐652. doi:10.1111/ene.14127
Stær K, Iranzo A, Stokholm M, et al. Microglial activation associated with a faster progression of nigrostriatal dysfunction in patients with isolated REM sleep behavior disorder. Mov Disord. 2020;35:S283.
Staer K, Iranzo A, Terkelsen MH, et al. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder. Eur J Neurol. 2023;31:e16101. doi:10.1111/ene.16101
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591‐1601. doi:10.1002/mds.26424
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270‐279. doi:10.1016/j.jalz.2011.03.008
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834‐840. doi:10.1097/00004647-199609000-00008
Patlak CS, Blasberg RG. Graphical evaluation of blood‐to‐brain transfer constants from multiple‐time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5(4):584‐590. doi:10.1038/jcbfm.1985.87
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129‐2170. doi:10.1002/mds.22340
Chaudhuri KR, Martinez‐Martin P, Brown RG, et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord. 2007;22(13):1901‐1911. doi:10.1002/mds.21596
Chaudhuri KR, Martinez‐Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006;21(7):916‐923. doi:10.1002/mds.20844
Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA‐AUT. Mov Disord. 2004;19(11):1306‐1312. doi:10.1002/mds.20153
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695‐699. doi:10.1111/j.1532-5415.2005.53221.x
Trenkwalder C, Kohnen R, Hogl B, et al. Parkinson's disease sleep scale—validation of the revised version PDSS‐2. Mov Disord. 2011;26(4):644‐652. doi:10.1002/mds.23476
Pavese N, Rivero‐Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F‐dopa PET study. NeuroImage. 2011;56(3):1463‐1468. doi:10.1016/j.neuroimage.2011.03.012
Fedorova TD, Knudsen K, Horsager J, et al. Dopaminergic dysfunction is more symmetric in dementia with Lewy bodies compared to Parkinson's disease. J Parkinsons Dis. 2023;13(4):515‐523. doi:10.3233/JPD-230001
Greenfield SA. A noncholinergic action of acetylcholinesterase (AChE) in the brain: from neuronal secretion to the generation of movement. Cell Mol Neurobiol. 1991;11(1):55‐77. doi:10.1007/BF00712800
Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK‐147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260(1):5‐8. doi:10.1016/s0304-3940(98)00943-4